Signs and symptoms: Adverse events associated with a sterilization device

被引:0
|
作者
Leiter, Valerie [1 ]
机构
[1] Simmons Univ, Dept Publ Hlth, 300 Fenway, Boston, MA 02115 USA
关键词
Adverse event; Diagnosis; Food and drug administration; Sterilization; Medical device; Reproductive health; Women's health; ESSURE HYSTEROSCOPIC STERILIZATION; LAPAROSCOPIC STERILIZATION; FEMALE STERILIZATION; TUBAL-STERILIZATION; FILSHIE CLIP; FOLLOW-UP; WOMEN; HEALTH; COMPLICATIONS; EXPERIENCE;
D O I
10.1016/j.socscimed.2024.116963
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Sterilization is now the most common contraceptive method used by women of in the U.S., and sterilization devices have played an important role in its increased popularity. This mixed methods study examines a random sample of 2500 U.S. Food and Drug Administration (FDA) adverse event reports made between 2006 and 2017 about Essure, a sterilization device. Quantitative coding was used to examine patient problems; pain and bleeding were reported most frequently. Qualitative coding analyzed impacts of symptoms on patients' everyday lives and patients' healthcare experiences, including intimate relationships, mothering, and paid employment. Findings suggest that some patients struggled when their reported "subjective" symptoms didn't result in "objective" clinical signs of problems, and when physicians dismissed or deflected their concerns in diagnostic encounters. This paper raises important issues regarding the symptoms patients associated with Essure, the diagnosis of device-driven disease and injury, and the FDA's regulation of medical devices.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Adverse events associated with mTOR inhibitors
    Pallet, Nicolas
    Legendre, Christophe
    [J]. EXPERT OPINION ON DRUG SAFETY, 2013, 12 (02) : 177 - 186
  • [42] Hematologic adverse events associated with temozolomide
    Villano, J. Lee
    Letarte, Nathalie
    Yu, Janny M.
    Abdur, Shakir
    Bressler, Linda R.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (01) : 107 - 113
  • [43] Bisphosphonate-associated adverse events
    Peter D. Papapetrou
    [J]. Hormones, 2009, 8 : 96 - 110
  • [44] Neurological adverse events associated with metronidazole
    Gelfand, Michael S.
    Cleveland, Kerry O.
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2017, 50 (04) : 598 - 598
  • [45] Adverse events associated to administration of omalizumab
    Gomez, M.
    Teijeiro, A.
    Jossen, R.
    Badellino, H.
    Jares, E.
    Yanez, A.
    Ivancevich, J.
    Croce, V
    Croce, J.
    Zernotti, M.
    Baena-Cagnani, C.
    [J]. ALLERGY, 2011, 66 : 673 - 674
  • [46] Statin-associated adverse events
    Golomb, BA
    Yang, E
    Denenberg, J
    Criqui, M
    [J]. CIRCULATION, 2003, 107 (07) : E7028 - E7029
  • [47] Adverse events associated with intravenous fosfomycin
    Florent, Amelie
    Chichmanian, Rose-Marie
    Cua, Eric
    Pulcini, Celine
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2011, 37 (01) : 82 - +
  • [48] Statin-Associated Adverse Events
    Yuet, Wei Cheng
    Khine, Htet
    Ahmad, Zahid
    [J]. CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2015, 7 : 17 - 24
  • [49] ADVERSE EVENTS ASSOCIATED WITH PANCREATIC ENDOTHERAPY
    Han, Samuel
    Tatman, Philip D.
    Attwell, Augustin
    Wani, Sachin B.
    Brauer, Brian C.
    Edmundowicz, Steven A.
    Hammad, Hazem T.
    Wagh, Mihir S.
    Shah, Raj J.
    [J]. GASTROINTESTINAL ENDOSCOPY, 2018, 87 (06) : AB578 - AB579